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Drug Resistance in Oncology
Edited by B. Teicher, New York: Marcel Dekker, 1993,
672 pp. $195.00.
This large book contains 26 generally informative and well-
written chapters addressing various aspects of cell or tumour
biology relating to therapeutic responsiveness. The list of
contributing authors is distinguished and includes many of
the leading experts in their fields.
In her preface, the editor explains her philosophy of re-
garding therapeutic resistance as a very broad issue involv-
ing, amongst other things, cellular biochemistry, tumour
physiology and host metabolism. She is clearly correct in
doing so, but I still cannot see why the book was given the
title which it carries. 'Drug resistance' may be a current
'buzzword(s)', but many of the chapters relate equally to
radiation responsiveness as to drug responsiveness, and
several have only the most remote connection with either.
Something along the lines of 'The Biology of Therapeutic
Response in Oncology' would have given a much more
accurate idea of the content.
In accord with the philosophy, the book begins with a
section entitled 'Physiological Resistance in Solid Tumours'.
This consists of seven chapters on topics such as the role of
blood flow, pH and oxygenation in tumour metabolism. The
second section, 'Biological Resistance', goes on to include
topics such as tumour cell heterogeneity, cell population
interactions and characterisation of the metastatic phenotype
within a total of six chapters. It is only upon reaching the
third section, 'Biochemical Resistance', that many readers
will, I suspect, find what they expect from the title of the
book. Five chapters discuss the fairly standard aspects of
drug resistance including GSH, P-glycoprotein and topoiso-
merases. Less predictable are chapters on 'Tumour cell drug
metabolism and drug resistance' (by D.E. Chapman and G.
Powis) and 'Oxazaphosphorine-specific acquired cellular
resistance' (by N. Sladek), which I found interesting and
valuable. (By the way, how many people can name at least
one oxazaphosphorine?) Section four, 'The Role of Hor-
mones, Growth Factors and Oncogenes', has five chapters,
including a particularly comprehensive and well-referenced
chapter on 'Antiestrogen resistance in breast cancer' (by R.
Clarke and M.E. Lippman). The final section, 'Clinical Re-
sistance', consists of only one, relatively short, chapter by
L.A. Ayash, T.S. Heman and E. Frei III. It seems to me
inappropriate that a very large book (672 pages) entitled
'Drug Resistance in Oncology' should contain only 14 pages
of text devoted specifically to consideration of clinical resist-
ance. A much more comprehensive account of topics such as
the role of non-cross-resistant therapies, high-dose therapy,
bone marrow transplantation, late dose intensification and
prolonged maintenance therapy would surely have been
valuable.
I am always curious as to what instructions were given to
authors regarding the detailed preparation of their chapters.
One gains the impression that no instructions were given as
to the reference system to be used. Most of the chapters use
standard Vancouver system. However, that by Chapman and
Powis uses the Harvard system, whilst that by Futscher and
Dalton has a reference list omitting the titles of the papers.
Not good enough! The efforts made by the authors in illust-
rating their chapters with appropriate figures and tables are
also extremely variable. The median number of figures plus
tables per chapter is 4 (range 0-21). I find it hard to believe
that, for example, the long chapter by Chapman and Powis
(30 pages of text, 260 references) is optimally presented with-
out a single figure or table.
It is always critical in assessing a book such as this to
consider how up to date the material is. The book was
published in February 1993 and, fairly predictably, contains
very few 1992 references. There are reasonable numbers of
1991 references, but also a smattering of 1991 (in press). I
also spotted a reference (in the Chapter by Kerbel and
MacDougall) to a paper, with Dr Kerbel as an author, given
as Int. J. Cancer 1990 (submitted), which is odd to say the
least. In late 1993, therefore, the potential reader has, as
usual, to ask the question whether, in such rapidly moving
fields, the material is sufficiently timely to be regarded as
definitive.
The volume contains an enormous amount of valuable
material together with some which is less valuable. It is also
enormously expensive. I think that it would have been a
better book had it attempted to be rather less ambitious and
somewhat more focused. It would certainly benefit from a
more appropriate title. I believe that it will be bought by
some major institutional libraries but I do not think that
many individuals will wish to pay the price.
P.R. Twentyman
Oxford Textbook of Pafliative Medicine
Edited by D. Doyle, G.W.C. Hanks & N. MacDonald,
Oxford: Oxford University Press, 1993, 845 pp.
The casual reader may well be daunted by the rather austere
covers of this weighty tome and by the number of
authors-103 in all. However, once Dame Cicely Saunders'
foreword has been digested, their appetite will be whetted for
the rest of the book. The publication of the Oxford Textbook
of Palliative Medicine is both timely and topical; it brings
together a wealth of experience from a wide range of discip-
lines and specialties and provides the most cohesive and
comprehensive guide to this evolving field yet available.
In their preface the editors do not address a specific target
audience. Cancer nurses, physicians and surgeons, candidates
preparing for professional examinations and members of
multidisciplinary palliative care teams will all undoubtedly
find it a useful resource. In addition, however, this book
contains 'something for everyone', including health
economists and purchasers of health care. Although the main
emphasis, particularly in the chapters on symptom control, is
on the palliation of symptoms in patients with malignant
disease, wider general principles are expounded which are
relevant to patients with symptoms irrespective of their
pathology. Specific chapters on paediatric palliative care and
palliative aspects of adult acquired immune deficiency syn-
dromes are especially welcome.
Slightly less than half the book is devoted to clear and
easily readable reviews of symptom management. These
chapters are based on both research and extensive clinical
experience, and most authors extend their discussion beyond
therapeutic strategies to a consideration of other aspects of
their subject, including its pathophysiology. Justifiably long
and detailed dissertations on the treatment of major symp-
toms such as pain and dyspnoea sit well alongside short but
pertinent sections on the management of problems as diverse
as sweating, lymphoedema and hiccoughs. Unfortunately,
areas where the interface between basic science and clinical
practice is particularly fruitful and where research is currently
active, such as the management of neuropathic pain, are
almost by definition already out of date. This is unavoidable,
and those chapters which suffer from this drawback are,
nonetheless, some of the most interesting.
The reader who still regards palliative care as purely 'ter-
minal care' will be surprised that only 14 of the 817 pages are
specifically devoted to the management of the 'terminal
phase' of illness. The basic premise that palliative care is